Impact of Intraoperative Neuromonitoring on Quality of Life and Functional Outcomes Following Microsurgical Resection of Cervical and Thoracic Intramedullary Spinal Cord Tumors in Adults - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Intraoperative Neuromonitoring on Quality of Life and Functional Outcomes Following Microsurgical Resection of Cervical and Thoracic Intramedullary Spinal Cord Tumors in Adults

  • By

  • Sebastian Siller

  • Sylvain Duell

  • Deniz Reyhaniye

  • Julian Kramer

  • Patrick N. Harter

  • Florian Ringel

  • Stefan Zausinger

  • Joerg-Christian Tonn

  • Andrea Szelenyi

  • March 25, 2026

Share

  • 1

    Intramedullary spinal cord tumors (IMSCTs) represent 2-4% of CNS neoplasms and 20-30% of spinal cord tumors in adults.

  • 2

    Microsurgical resection is crucial for preventing neurological deficits and improving survival in patients with IMSCTs.

  • 3

    This study is the first prospective analysis evaluating neurological, functional, and quality-of-life outcomes post-IMSCT resection.

  • 4

    Detailed assessments were conducted preoperatively and at multiple follow-up points to gauge patient recovery and satisfaction.

  • 5

    The study aims to enhance understanding of health-related outcomes and inform decision-making for IMSCT treatment.

Original Source(s)

Impact of Intraoperative Neuromonitoring on Quality of Life and Functional Outcomes Following Microsurgical Resection of Cervical and Thoracic Intramedullary Spinal Cord Tumors in Adults

  • by Sebastian Siller, Sylvain Duell, Deniz Reyhaniye, Julian Kramer, Patrick N. Harter, Florian Ringel, Stefan Zausinger, Joerg-Christian Tonn, Andrea Szelenyi

  • March 25, 2026

Related Content

Salvage microsurgery for vestibular schwannoma after failed stereotactic radiosurgery: a multi-institutional retrospective study

FDA Clears Olastrocel Trial Expansion

Additional patients with ongoing opioid use are being enrolled as Creative Medical prepares for potential Phase 3 discussions with the FDA.

External validation of a machine learning-based web application for personalized testing of objective functioning using the five-repetition sit-to-stand test